RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment

Summary

The purpose of this prospective and multicentric study is to evaluate the effectiveness and tolerability of rimegepant as preventive migraine treatment in a cohort of episodic or chronic migraine patients.

Conditions

• Migraine
• Migraine With Aura
• Migraine Without Aura
• Chronic Migraine

Interventions

DRUG

Rimegepant 75 mg

Patients using Rimegepant 75 mg orally disintegrating tablet every other day as migraine prevention

Sponsors & Collaborators

• IRCCS National Neurological Institute "C. Mondino" Foundation

  collaborator OTHER

• Società Italiana per lo Studio delle Cefalee

  collaborator OTHER

• Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari

  collaborator OTHER

• Università degli Studi dell'Aquila

  collaborator OTHER

• University of Roma La Sapienza

  collaborator OTHER

• Azienda Ospedaliero Universitaria Policlinico Modena

  collaborator OTHER

• Ospedale di Piove di Sacco

  collaborator UNKNOWN

• Azienda Ospedaliero-Universitaria di Parma

  collaborator OTHER

• Azienda Ospedaliera S. Maria della Misericordia

  collaborator OTHER

• A.O.U. Città della Salute e della Scienza

  collaborator OTHER

• Cliniche Humanitas Gavazzeni

  collaborator OTHER

• University of Campania Luigi Vanvitelli

  collaborator OTHER

• Ospedale Santo Stefano

  collaborator OTHER

• Azienda Policlinico Umberto I

  collaborator OTHER

• Auxologico San Luca

  collaborator OTHER

• Asst Degli Spedali Civili Di Brescia

  collaborator OTHER

• Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta

  collaborator OTHER

• University of Florence

  lead OTHER

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2024-03-26

Primary Completion

2027-01-01

Completion

2027-09-30

Countries

• Italy

Study Locations